Cibus Inc

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cibus Inc reports Q2 loss, eyes commercial transition and growth

Cibus Inc's Q2 2023 performance reflects increased expenses and a net loss, with a focus on commercial transition.
Strengths lie in the efficient Trait Machine process, optimistic market outlook, and strategic collaborations.
Challenges include financial uncertainties, regulatory complexities, and balancing R&D with commercial goals.
Opportunities encompass product expansion, technology extension, M&A potential, and favorable market regulations.

Cibus Inc transitions to commercial focus with promising trait developments

Cibus Inc is transitioning to a commercial focus with promising trait developments in major crops.
Despite a net loss in Q3 2023, the company remains optimistic about future growth opportunities.
Regulatory advancements and strategic realignment position Cibus for potential market expansion.

Cibus Inc excels in gene editing transition, eyes industry growth

Cibus Inc's Q4 performance showcased successful transition, strong market focus, and strategic financial management.
While facing challenges related to merger impacts and spending adjustments, the company remains optimistic about growth opportunities.
With a clear vision for innovation and market leadership, Cibus is poised for continued success in the gene editing agricultural sector.

Cibus Inc (CBUS) reports strong Q1 performance amidst gene editing advancements

Cibus Inc (CBUS) had a strong Q1 2024 performance with revenue exceeding expectations, driven by increased customer demand. The company is navigating challenges in market penetration and increased expenses but sees opportunities in regulatory advances and advancing their gene editing platforms.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cibus, Inc. engages in the research and development of plant traits to seed companies for royalties. It focuses on using gene editing to develop productivity traits in major agricultural crops such as Canola, Rice, Soybean, Corn and Wheat. The company was founded by Rory Riggs, Peter Beetham and Greg Gocal in 2010 and is headquartered in San Diego, CA.

NEW YORK, NY / ACCESSWIRE / July 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cibus, Inc. ("Cibus, Inc.") (NASDAQ:CBUS) concerning possible violations of federal securities laws. Bonitas Research ("Bonitas") issued a report on June 4, 2024, alleging that it had "found no evidence that Cibus' gene-editing technology brings desirable new crops to market.

An Investigation Has Commenced on Behalf of Cibus, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your CBUS Losses.

NEW YORK, NY / ACCESSWIRE / July 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cibus, Inc. ("Cibus, Inc.") (NASDAQ:CBUS) concerning possible violations of federal securities laws. Bonitas Research ("Bonitas") issued a report on June 4, 2024, alleging that it had "found no evidence that Cibus' gene-editing technology brings desirable new crops to market.

Shareholder Rights Advocates at Levi & Korsinsky Investigate Cibus, Inc. (CBUS) Regarding Possible Securities Fraud Violations

NEW YORK, NY / ACCESSWIRE / July 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cibus, Inc. ("Cibus, Inc.") (NASDAQ:CBUS) concerning possible violations of federal securities laws. Bonitas Research ("Bonitas") issued a report on June 4, 2024, alleging that it had "found no evidence that Cibus' gene-editing technology brings desirable new crops to market.

CBUS STOCK ALERT: Levi & Korsinsky Notifies Cibus, Inc. Investors of an Ongoing Investigation

Cibus, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights – CBUS

ATTENTION CBUS SHAREHOLDERS: Investors who lost money on Cibus, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation

NEW YORK, NY / ACCESSWIRE / July 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cibus, Inc. ("Cibus, Inc.") (NASDAQ:CBUS) concerning possible violations of federal securities laws. Bonitas Research ("Bonitas") issued a report on June 4, 2024, alleging that it had "found no evidence that Cibus' gene-editing technology brings desirable new crops to market.

Did Cibus, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - CBUS

NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cibus, Inc. ("Cibus, Inc.") (NASDAQ:CBUS) concerning possible violations of federal securities laws. Bonitas Research ("Bonitas") issued a report on June 4, 2024, alleging that it had "found no evidence that Cibus' gene-editing technology brings desirable new crops to market.

CBUS ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Cibus, Inc.

NEW YORK , July 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Cibus, Inc. ("Cibus" or the "Company") (NASDAQ: CBUS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cibus, Inc. - CBUS\

Additional patents issued for 10 plant trait and editing families in the past two quarters. Strengthens Cibus' intellectual property portfolio in its Pod Shatter Reduction (PSR), Herbicide Tolerances (HTs), High Fiber Wheat and Improved Quality Alfalfa trait families.

Cibus Expands its Intellectual Property Coverage for Plant Gene Editing and Traits

SAN DIEGO, June 21, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of securities laws by Cibus, Inc. (NASDAQ: CBUS). We are looking into whether the Company or its executives failed to disclose vital information to investors, leading to losses on their investments. If you have purchased Cibus securities and have experienced losses, we encourage you to join our investigation to potentially make claims and recover under federal securities laws.

Breaking News: Johnson Fistel, LLP Investigates Cibus Following Short Report

BOSTON, June 18, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Cibus, Inc. (Nasdaq: CBUS) for potential securities law violations. Investors who have lost money in their Cibus investment should  contact the firm  to learn more about how they might recover those losses.

Cibus ALERT: Cibus, Inc. Investigated for Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm

BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Cibus, Inc. (Nasdaq: CBUS) for potential securities law violations. Investors who have lost money in their Cibus investment should  contact the firm  to learn more about how they might recover those losses.

SHAREHOLDER ALERT: Cibus, Inc. Investigated for Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm

NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cibus, Inc. (“Cibus” or the “Company”) (NASDAQ: CBUS) on behalf of Cibus stockholders. Our investigation concerns whether Cibus has violated the federal securities laws and/or engaged in other unlawful business practices.

CIBUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Cibus, Inc. on Behalf of Cibus Stockholders and Encourages Investors to Contact the Firm

BOSTON, MA / ACCESSWIRE / June 5, 2024 / Block & Leviton is investigating Cibus, Inc. (Nasdaq:CBUS) for potential securities law violations. Investors who have lost money in their Cibus investment should contact the firm to learn more about how they might recover those losses.

Cibus Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation

ATLANTA, June 05, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Cibus, Inc. (“Cibus” or the “Company”) (NASDAQ: CBUS) complied with federal securities laws. On June 4, 2024, Bonitas Research published a report alleging, among other things, that “investors have been duped into believing a promotional management team about an over-hyped technology previously tried, tested, and failed by some of the world's largest seed manufacturers and distributors to provide exit liquidity for early-stage Cibus investors.” Following this news, the price of the Company's stock dropped.

Investigation Into Cibus, Inc. (CBUS) Announced by Holzer & Holzer, LLC

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Cibus, Inc. (“Cibus” or the “Company”) (NASDAQ: CBUS) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Cibus investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Cibus, Inc. (CBUS) on Behalf of Investors

SAN DIEGO, June 05, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced its participation in the following June investor events.

Cibus to Participate in Upcoming June Investor Events

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Cibus, Inc. (“Cibus” or the “Company”) (NASDAQ: CBUS) investors concerning the Company's possible violations of federal securities laws. On June 4, 2024, Bonitas Research published a report alleging, among other things, that there is “no evidence that Cibus' gene-editing technology brings desirable new crops to market,” and, instead, there are “farmer complaints of lower crop yields and lost r.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Cibus, Inc. (CBUS) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Cibus, Inc. (“Cibus” or the “Company”) (NASDAQ: CBUS) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On June 4, 2024, Bonitas Research published a report alleging, among other things, that there is “no evidence that Cibus' gene-editing technology brings desirable new crops to market,.

The Law Offices of Frank R. Cruz Announces Investigation of Cibus, Inc. (CBUS) on Behalf of Investors

Cibus, Inc. investigated for potential securities law violations. Investors who have lost money in their Cibus investment should contact Block & Leviton.

Cibus Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm

Cibus Applauds the Canadian Food Inspection Agency's (CFIA) New Guidelines for Plants Developed Using Gene Editing Cibus Applauds the Canadian Food Inspection Agency's (CFIA) New Guidelines for Plants Developed Using Gene Editing

Canada Added to a Growing List of Countries Regulating Cibus' Gene Editing Technologies Similar to Conventional Breeding

Cibus, Inc. (NASDAQ:CBUS ) Q1 2024 Results Conference Call May 9, 2024 4:30 PM ET Company Participants Wade King - Chief Financial Officer Rory Riggs - Co-Founder, Chief Executive Officer and Chairman Peter Beetham - Co-Founder, President and Chief Operating Officer Conference Call Participants Bobby Burleson - Canaccord Genuity Carol Cheung - Jefferies Steve Byrne - Bank of America Operator Good afternoon, and welcome to the Cibus First Quarter 2024 Results Conference Call. [Operator Instructions] Please also note today's event is being recorded.

Cibus, Inc. (CBUS) Q1 2024 Earnings Call Transcript

Cibus (CBUS) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $1.01. This compares to loss of $5.45 per share a year ago.

Cibus (CBUS) Reports Q1 Loss, Tops Revenue Estimates

SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report first quarter 2024 financial results on Thursday, May 9, 2024. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates.

Cibus to Report First Quarter 2024 Financial Results on May 9, 2024 and Host Conference Call

Cibus (CBUS) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1.12. This compares to loss of $3 per share a year ago.

News for Cibus Inc Stock (CBUS)